OR IGINA L AR TI CLE Pulmonary function patients ulcerative colitis relationship disease severity Ajesh Goyal Uday C Ghoshal Alok Nath Shikha Jindal Samir Mohindra Departments Gastroenterology Pulmonology Sanjay Gandhi Postgraduate Institute Medical Sciences Lucknow India doi101002jgh312005 Key words inﬂammatory bowel disease pulmonary function test small airways spirometer Accepted publication 7 August 2017 Correspondence Dr Uday C Ghoshal Professor Department Gastroenterology Sanjay Gandhi Postgraduate Institute Medical Sciences Rae Bareli Road Lucknow 226014 India Email udayghoshalgmailcom Introduction Abstract Background Aim Ulcerative colitis UC patients extraintestinal systemic manifestations As studies frequency predictors pulmonary involvement patients UC inconsistent undertook prospective study Methods Eightyseven patients UC remission 49 563 active disease 38 436 median age 40 years range 1666 55 622 males 50 healthy controls median age 38 years range 1469 34 68 males underwent pulmonary function tests PFTs including forced expiratory volume 1 s FEV1 forced vital capacity FVC Tiffeneau value FEV1FVC midexpiratory ﬂow rate diffusion lung capacity carbon monoxide spirometer Results Subjects UC control comparable age gender PFT abnormal 24 275 patients active disease 1538 394 remission 949 184 1 2 control P 0005 Of 24 patients abnormal PFT small airway restrictive obstructive defects detected 12 50 11 458 1 42 patients respectively Patients abnormal PFT active dis ease 1524 625 vs 2363 365 P 003 No relation PFT abnormalities age sex duration disease body mass index serum albumin hemo globin levels extraintestinal manifestation arthritisarthralgia drugs treat UC Conclusion UC patients active disease abnormal pulmonary functions predominant involvement small airways Active UC associated abnormal PFT disease remission residual elevated functional Lung involvement ulcerative colitis UC ﬁrst reported 19761 increasingly reported recent years Since ﬁrst report abnormal pulmonary function tests PFTs reported 1755 patients UC26 including decrease gas transfer factor diffusion lung capacity carbon monoxide DLCO78 capacity FRC9 decrease maximal midexpiratory ﬂow rate MEFR10 increased frequency bronchial hyperresponsiveness11 studies abnormalities PFT found1012 Various respiratory abnormalities reported patients UC include obstructive interstitial lung disease13 small large airway disorders1415 increase bronchial sensitivity11 bronchi tis bronchiectasis1617 bronchiolitis oblitrans18 Thus important respiratory manifestations recognized trea ted early Otherwise lead irreversible changes airway wall endstage lung disease However information types respiratory dys function relation disease activity factors inﬂuen cing pulmonary dysfunction patients UC insufﬁcient inconsistent Also little data available India regard ing pulmonary function abnormalities patients UC1921 Accordingly undertook study following aims evaluate frequency type pulmonary dys function patients UC ii evaluate predictors abnormal pulmonary functions Methods Patients Eightyseven patients UC diagnosis based characteristic clinical features colonoscopy histopathological examination colonic mucosa exclusion infective cause attending Gastroenterology outpatient multilevel teaching hospital northern India subjected PFT obtaining informed consent Detailed clinical history including demo graphic proﬁle duration disease severity activity clinical course recorded Patients major surgical operation skeletal abnormalities thorax history asthma familial atopy peripheral eosinophilia previous lung disease active smoking 32 JGH Open An open access journal gastroenterology hepatology 1 2017 3237 2017 The Authors JGH Open An open access journal gastroenterology hepatology published Journal Gastroenterology Hepatology Foundation This open access article terms Creative Commons AttributionNonCommercial License permits use distribution reproduction medium provided original work properly cited commercial purposes John Wiley Sons Australia Ltd A Goyal et al Pulmonary functions ulcerative colitis chronic obstructive pulmonary disease COPD signs pulmo nary infection endstage renal disease ESRD coronary artery valvular heart diseases morbid obesity body mass index BMI 35 kgm2 pregnancy age 14 70 years use nonsteroidal antiinﬂammatory drugs lack compliance performing PFT excluded study Duration disease The duration disease deﬁned period date onset symptoms date PFT Disease activity Patients divided groups depending activity UC active disease remission Patients active disease classiﬁed mild moderate severe Truelove score22 This score includes stool frequency occurrence blood stools fever hemoglobin Hb levels erythrocyte sedimentation rate ESR Patients considered clinical remission stools day blood fever tachycardia normal Hb determinations ESRs23 Extent disease Extent disease assessed colonoscopy proctitis leftsided colitis pancolitis Proctitis deﬁned involvement rectum leftsided colitis left colon splenic ﬂexure pancolitis extensive dis ease splenic ﬂexure Healthy controls A group age sexmatched healthy controls taken general population PFT Ethical considerations Written informed consent taken patients controls The study protocol approved ethics committee institution Pulmonary function test Pulmonary function testing performed spirometer 2010 Ganshorn Medizin Elec tronic GmbH Industries Trasse 68 97618 Nieder Lauer Ger Software version LF 85 measure predicted forced vital capacity FVC predicted forced expiratory volume 1 s FEV1 ratio FEV1FVC mean expira tory volume 2575 MEV2575 A minimum acceptable reproducible maneuvers obtained according standard recommended American Thoracic Society Results expressed percentage normal gender age height percent predicted DLCO measured single breath test24 2010 Ganshorn Medizin Electronic GmbH Industries Trasse 6 8 97618 Software version LF 8 The individual results classiﬁed normal restric tive obstructive small airway disease American Thoracic Society guidelines PFT25 Normal physiology deﬁned measurements 80 predicted restrictive defect reduced 80 predicted FVC FEV1FVC ratio 70 predicted reduced DLCO 80 predicted obstructive defect reduced FEV1 normal FVC low FEV1FVC ratio 70 predicted Small airway dis ease deﬁned reduced FEV1 70 predicted low FEV1 FVC 70 predicted ratio reduced MEF2575 60 predicted Statistical analysis Sample size calculation Assuming frequency abnormal PFT subjects UC healthy controls 20 4 respectively sample size calculated considering 15 cases control twosided conﬁdence interval 95 power 80 Pvalue 005 signiﬁcant number cases controls needed 72 48 respec tively For calculation sample size EpiInfo software version 7 Center Disease Control Prevention Atlanta GA USA Data analysis Statistical analysis performed SPSS version 15 SPSS Inc Chicago IL USA Continuous data expressed median range Continuous categorical variables analyzed MannWhitney Utest chi square test Yates correction applicable respectively Intergroup comparison variables performed KruskalWallis Htest Spearman Pearson correlation coefﬁcient ﬁnd relationship data continuous variables depending distribution Pvalues 005 considered signiﬁcant Results Demographic clinical characteristics UC patients controls Table 1 summarizes demographic clinical laboratory parameters patients UC n 87 control n 50 Patients UC healthy controls comparable age median 40 years range 1666 median 38 years range 1469 P 07 gender male 55 632 34 68 P 05 Duration disease 48 range 1240 months Fortynine 586 patients active disease 12 arthralgia 3 arthritis 9 peripheral arthritis arthralgia extraintestinal manifestation UC Three patients exsmokers nonsmokers All controls nonsmokers None patients occupational family history respiratory disease atopy major abdom inal thoracic surgery No patient signiﬁcant abnormal ity chest radiograph PFT UC patients Twentyfour 276 UC patients 1 2 control showed abnormal PFT P 001 Of 24 patients abnormal PFT small airway restrictive obstructive defects detected 12 50 11 458 1 42 patients respectively UC patients signiﬁcantly low FEV1 FEV1FVC MEF2575 peak expiratory ﬂow rate PEFR DLCO values compared controls P 005 shown Table 1 PFT values abnormal 3 24 125 15 42 357 6 21 286 patients proctitis leftsided colitis pancolitis respectively shown Table 2 Of 24 patients abnormal PFT 5 symptoms chronic cough 3 dyspnoea exertion 2 Relationship disease activity extent colitis extraintestinal manifestations treatment nutrition status PFT The demographic clini cal laboratory parameters UC patients normal abnormal PFT shown Table 2 In patients abnormal PFT 15 625 active disease 9 375 JGH Open An open access journal gastroenterology hepatology 1 2017 3237 2017 The Authors JGH Open An open access journal gastroenterology hepatology published Journal Gastroenterology Hepatology Foundation 33 John Wiley Sons Australia Ltd Pulmonary functions ulcerative colitis A Goyal et al Table 1 Demographic clinical laboratory parameters PFT patients controls Parameters Age years median range Sex males n Mean duration disease months Drugs ASA Steroids Azathioprine Methotrexate Sulfasalazine Extent disease Proctitis Leftsided colitis Pancolitis Disease activity Remission Relapse Mild Moderate Severe Hemoglobin gdL Albumin gdL BMI kgm2 median range Abnormal PFT n FEV1 median range FEV1FVC median range FVC median range MEF2575 median range PEFR median range DLCO median range Patients n 87 40 1666 55 632 48 1240 78 897 39 448 16 184 2 23 9 103 24 276 42 483 21 241 49 586 38 414 6 158 9 237 23 605 118 53172 39 1649 209 148342 24 276 8951171 86 63120 87 49145 77 24176 7938122 108 68213 Healthy controls n 50 38 1469 34 68 Pvalue 070 057 231 159349 1 2 98 71181 91 80118 925 80145 915 67176 965 70140 122 82213 083 001 0000 0048 0005 0000 0000 0000 MannWhitney Utest continuous data chisquare test categorical data All continuous data presented median range For cate gorical data ﬁgures parenthesis indicate percentages ASA amino salicylic acid BMI body mass index DLCO diffusion lung capacity carbon monoxide FEV1 forced expiratory volume 1 s FVC forced vital capacity MEF mean expiratory ﬂow PEFR peak expiratory ﬂow rate PFT pulmonary function test remission P 003 Patients proctitis tended normal abnormal PFT 125 vs 333 n 006 Table 2 Nutritional status BMI serum albumin Hb signiﬁcantly different patients normal abnormal PFT Of 87 patients UC 12 138 peripheral joint arthralgiaarthritis Frequency abnormal PFT comparable patients arthralgiaarthritis 424 166 vs 855 145 P ns There relationship treatment UC different drugs abnormal PFT Table 2 UC patients active disease remission Patients active disease comparable age gender duration disease patients remission There sig niﬁcant difference FEV1 FEV1FVC MEF2575 PEFR DLCO P 005 patients UC active disease remission Table 3 different controls Fig 1 Discussion In present study patients UC abnormal PFT comparison healthy controls ii patients abnormal PFT small airway involvement iii impairment PFT related activity disease Patients UC known extraintestinal manifestations including pulmonary involvement Douglas et al26 PFT abnormalities 32 patients UC However patients study smokers In study participants nonsmokers exsmokers 3 87 possible negative impact smoking PFT results negligible Sethy et al19 Tzanakis et al14 deranged PFT 17 n 85 27 n 51 patients UC We UC patients signiﬁcantly lower DLCO compared controls The reduction DLCO indicate involvement lung parenchyma This observation indi cates subclinical interstitial lung disease present patients UC known reduction diffusing capacity lungs common early manifestation interstitial lung disease27 The observed reduction DLCO study consistent presence sub clinical alveolitis28 supporting hypothesis migration inﬂammation bloodstream intestine lung parenchyma airway mucosa29 34 JGH Open An open access journal gastroenterology hepatology 1 2017 3237 2017 The Authors JGH Open An open access journal gastroenterology hepatology published Journal Gastroenterology Hepatology Foundation John Wiley Sons Australia Ltd A Goyal et al Pulmonary functions ulcerative colitis Table 2 Demographic clinical laboratory parameters ulcerative colitis patients abnormal normal PFT Parameters Age years median range Sex males n Median duration disease months Extent disease Proctitis Leftsided colitis Pancolitis Severity disease Remission Active Mild Moderate Severe BMI kgm2 Albumin mgdL Hemoglobin gdL Treatment disease 5ASA Salazopyrine Azathioprine Methotrexate PFT abnormal n 24 36 1856 16 666 48 1180 3 125 15 625 6 25 9 375 15 625 1 42 5 208 9 375 2305 159349 375 1748 11 67153 21 3 4 0 PFT normal n 63 41 1666 39649 48 6240 21 333 27 429 15 238 40 635 23 365 5 79 4 63 14 222 208 148342 39 1649 118 53172 57 6 12 2 Pvalue 0677 0805 0426 006 0149 0908 0033 0033 0371 0444 0773 0784 0604 0409 0475 0475 0533 0522 MannWhitney Utest continuous data chisquare test categorical data All continuous data presented median range For cate gorical data ﬁgures parenthesis indicate percentages ASA amino salicylic acid BMI body mass index PFT pulmonary function test Table 3 Clinical proﬁle patients remission active colitis Parameters Age years median range Sex males n Mean duration disease months Abnormal PFT n Obstructive pattern n Small airway disease n Restrictive pattern n FEV1 median range FEV1FVC median range FVC median range MEF2575 median range PEFR median range DLCO median range MEF25 median range MEF75 median range BMI kgm2 Hemoglobin gdL Albumin gdL Remission n 49 40 1662 33 673 48 6280 9184 0 7 778 2 222 89 54171 84 66120 87 65145 77 24176 82 49122 112 80213 69 23261 81 25131 218 154342 129 53172 4 2149 Active colitis n 38 371666 22579 36 1240 15 395 1 67 5 333 9 60 865 51124 88 63100 83 49128 775 33135 755 38108 105 68143 635 33138 76 35140 195 148295 106 67138 335 1645 Pvalue 0768 0380 0548 0033 1000 0089 0105 0504 0779 0271 0745 0086 0221 0784 0346 0057 0000 0000 MannWhitney Utest continuous data chisquare test categorical data All continuous data presented median range For cate gorical data ﬁgures parenthesis indicate percentages BMI body mass index DLCO diffusion lung capacity carbon monoxide FEV1 forced expiratory volume 1 s FVC forced vital capacity MEF mean expiratory ﬂow PEFR peak expiratory ﬂow rate PFT pulmonary function test Small airway function decreased MEF2575 signiﬁ cantly impaired patients UC compared controls study Tzanakis et al5 alteration function small airways independent presence atopy patients UC pulmonary symptoms Mild airway inﬂam mation secondary primary inﬂammation intestinal JGH Open An open access journal gastroenterology hepatology 1 2017 3237 2017 The Authors JGH Open An open access journal gastroenterology hepatology published Journal Gastroenterology Hepatology Foundation 35 John Wiley Sons Australia Ltd Pulmonary functions ulcerative colitis A Goyal et al Figure 1 FEV1 FEV1FVC MEFR DLCO patients remission FEV1 remission vs controls P 0003 relapse vs controls P 0001 remission vs relapse P 0504 FEV1FVC remission vs controls P 0005 relapse vs controls P 0049 remission vs relapse P 0595 MEFR remission vs controls P 000 relapse vs controls P 000 remission vs relapse P 0745 DLCO remission vs controls P 0007 relapse vs controls P 0002 remission vs relapse P 0784 DLCO diffusion lung capacity carbon monoxide FEV1 forced expiratory volume 1 s FVC forced vital capacity MEFR midexpiratory ﬂow rate control relapse mucosa explain alteration small airways seen study Changes bronchial epithelium consisting basal cell hyperplasia basement membrane thickening submuco sal inﬂammation overall increase thickness epi thelium reported bronchial biopsies patients UC coexisting bronchial suppuration30 All UC patients active remission abnormal PFT compared healthy subjects study Thus suggest patients remission UC continue deranged PFT Also study FEV1 FEV1FVC MEFR DLCO signiﬁcantly decreased patients active inactive disease compared trols Patients active disease lower PEFR DLCO inactive disease statistically signiﬁcant Herrlinger et al11 MohamedHussein13 FEV1 FVC signiﬁcantly decreased patients active disease compared inactive disease In study Fehmi et al15 signiﬁcantly decreased FEV1 FVC DLCO PFT active remission phases patient compared control Among patients deranged PFT 1 42 obstructive 12 50 small airway disease 11 458 restrictive pattern lung involvement Sethy et al21 reported restrictive pattern small airway disease 16 8 UC patients n 51 abnormal PFT Godet et al9 PFT abnormalities obstructive pattern abnormal DLCO restrictive pattern 53 227 288 15 patients UC respectively In Indian study 27 95 285 patients inﬂammatory bowel disease 83 UC 12 Crohns disease small airway obstruction seen 18 restrictive defect 6 mixed defect 3 patients31 Our results somewhat accordance study31 A higher number patients disease limited rec tum normal PFT 333 vs 125 P 006 study This explained higher chances lung involvement inﬂammatory process extent UC increases rectum colon Data relationship extent UC PFT abnormalities scanty litera ture Hence studies higher number patients needed know inﬂuence disease extent pulmonary functions In contrast study showed lack relationship BMI PFT results Herrlinger et al weak cor relation inspiratory vital capacity r 025 P 005 BMI FEV1 r 018 P 089 DLCO r 024 P 0203 Patients severe disease activity perform worse PFT general sickness fatigue Apart poor compliance performing tests exclusion criterion study patients remission clinical symptoms formed signiﬁcantly worse healthy controls This strong argument inﬂuence disease pulmonary function strengthens hypothesis observed abnormalities lung function tests represent real extraintestinal manifesta tion UC Limitation study lack high resolution CT scan thorax patients abnormal PFT longterm characterized respiratory abnormality Also 36 JGH Open An open access journal gastroenterology hepatology 1 2017 3237 2017 The Authors JGH Open An open access journal gastroenterology hepatology published Journal Gastroenterology Hepatology Foundation John Wiley Sons Australia Ltd A Goyal et al Pulmonary functions ulcerative colitis followup patients abnormal PFT required know develop clinically signiﬁcant lung disease end stage lung failure We conclude onefourth patients UC abnormal PFT The impairment pulmonary functions cor disease Pathophysiological relates activity mechanisms clinical relevance need studied References 1 Kraft SC Earle RH Roesler M et al Unexplained bronchopulmonary disease inﬂammatory bowel disease J Pediatr Gastroenterol Nutr 2009 48 14251 2 Godet PG Cowie R Woodman RC Sutherland LR Pulmonary patients ulcerative colitis Am function abnormalities J Gastroenterol 1997 92 11546 3 Herrlinger KR Noftz MK Dalhoff K Ludwig D Stange EF Fellermann K Alterations pulmonary function inﬂammatory bowel disease frequent persist remission Am J Gastroenterol 2002 97 37781 4 MohamedHussein AA Mohamed NA Ibrahim ME Changes pul monary function patients ulcerative colitis Respir Med 2007 101 97782 5 Yilmaz A Yilmaz Demirci N Hosgün D et al Pulmonary involve ment infammatory bowel disease World J Gastroenterol 2010 16 49527 6 Ates F Karincaocid1glu M Hacievlıyagıl SS Yalniz M Seçkın Y Alterations pulmonary function tests inﬂammatory bowel diseases Turk J Gastroenterol 2011 22 2939 7 Heatley RV Thomas P Prokipchuk EJ Gauldie J Sieniewicz DJ Bienenstock J Pulmonary function abnormalities patients inﬂammatory bowel disease Q J Med 1982 203 24150 8 Kuzela L Vavrecka A Prikazska M et al Pulmonary complications patients inﬂammatory bowel disease Hepatogastroenterology 1999 46 171419 9 Desai BN Kochhar R Behera D et al Pulmonary function changes patients idiopathic ulcerative colitis Lung India 1997 15 613 10 Johnson NM Mee AS Jewell DP Clarke SW Pulmonary function inﬂammatory bowel disease Digestion 1978 18 41618 11 Mansi A Cucchiara S Greco L et al Bronchial hyperresponsiveness children adolescents Crohns disease Am J Respir Crit Care Med 2000 161 10514 12 Tzanakis N Bouros D Samiou M et al Lung function patients inﬂammatory bowel disease Respir Med 1998 92 51622 13 Camus P Piard F Ashcroft T Gal AA Colby TV The lung inﬂam matory bowel disease Medicine Baltimore 1993 72 15183 14 Tzanakis N Samiou M Bouros D Mouzas J Kouroumalis E Siafakas NM Small airways function patients inﬂammatory bowel disease Am J Respir Crit Care Med 1998 157 3826 15 Spira A Grossman R Balter M Large airway disease associated inﬂammatory bowel disease Chest 1998 113 17236 16 Kraft SC Earle RH Roesler M Esterly JR Unexplained broncho pulmonary disease inﬂammatory bowel disease Arch Intern Med 1976 136 4549 17 Mahadeva R Walsh G Flower CD Shneerson JM Clinical radi ological characteristics lung disease inﬂammatory bowel disease Eur Respir J 2000 15 418 18 Mahajan L Kay M Wyllie R Steffen R Goldfarb J Ulcerative coli tis presenting bronchiolitis obliterans organizing pneumonia pediatric patient Am J Gastroenterol 1997 92 21234 19 Sethy PK Dutta U Aggarwal AN et al Pulmonary hematologi cal alteration idiopathic ulcerative colitis Indian J Gastroenterol 2003 22 1769 20 Tiwari RS Pruthi HS Lakhera SC Kain TC Pulmonary functions ulcerative colitis J Assoc Physicians India 1989 37 7734 21 Sharma MP Kar P Pulmonary functions ulcerative colitis J Assoc Physicians India 1985 33 61314 22 Truelove SC Witts LJ Cortisone ulcerative colitis Br Med J 1955 2 10418 23 Kjeldsen J Schaffalitzky Muckadell OB Assessment disease severity activity inﬂammatory bowel disease Scand J Gastroenterol 1993 28 19 24 MacIntyre N Crapo RO Viegi G et al Standardisation single breath determination carbon monoxide uptake lung Eur Respir J 2005 26 72035 25 MacIntyre N Crapo RO Viegi G et al ATSERS TASK FORCE lung function test Eur Respir J 2005 26 standardisation 94868 26 Douglas JG McDonald CF Leslie MJ Gillon J Crompton GK McHardy GJ Respiratory impairment inﬂammatory bowel disease vary disease activity Respir Med 1989 83 38994 27 Andus T Gross V Casar I et al Activation monocytes inﬂammatory bowel disease Pathobiology 1991 59 16670 28 Wallaert B Subclinical alveolitis immunologic systemic disorders Lung 1990 168 Suppl 97483 29 Louis E Louis R Drion V et al Increased frequency bronchial hyper responsiveness patients inﬂammatory bowel disease Allergy 1995 50 72933 30 Higenbottam T Cochrane GM Clark TJ Turner D Millis R Seymour W Bronchial disease ulcerative colitis Thorax 1980 35 5815 31 Desai D Patil S Udwadia Z Maheshwari S Abraham P Joshi A Pulmonary manifestations inﬂammatory bowel disease prospec tive study Indian J Gastroenterol 2011 30 2258 JGH Open An open access journal gastroenterology hepatology 1 2017 3237 2017 The Authors JGH Open An open access journal gastroenterology hepatology published Journal Gastroenterology Hepatology Foundation 37 John Wiley Sons Australia Ltd